Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 6Terminated 2

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Head and Neck Neoplasms 1

Interventions

Cyclophosphamide 47aldesleukin 30fludarabine phosphate 26fludarabine 24Carboplatin 18Rituximab 16Interleukin-2 16Cisplatin 16Bevacizumab 162,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 16Radiotherapy 15Paclitaxel 15Magnetic Resonance Spectroscopy 14Bortezomib 14Filgrastim 13Doxorubicin 13Oxaliplatin 12Erlotinib Hydrochloride 12Trastuzumab 11Leucovorin 11Etoposide 11Biopsy 11Taxes 10Radiation 10Fluorouracil 10alvocidib 9Specimen Handling 9Sorafenib 9Docetaxel 9Dexamethasone 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × NIH × perifosine × Clear all
NCT00058214 2015-02-23

Perifosine in Treating Patients With Recurrent Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
25 enrolled 5 charts
Genitourinary

Prostatic Neoplasms

NCT00062387 2013-06-03

Perifosine in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
46 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡